Novartis Annual Report 2002 Looking for answers Search Home Financial highlights Letter from Daniel Vasella Amazing Patient Stories...
Pharmaceutical Product List S - Novartis.com Search Novartis.com - Go Novartis.com Home Products Pharmaceutical Best Sellers Pharmaceuticals CIBA Vision Animal Health Over the Counter Infant and Baby Medical Nutrition Diseases & Conditions About Novartis Investor Relations Media Relations Careers Corporate Citizenship Business Development Our Mission Our Businesses Leadership & Governance Research & Development Foundations...
BioPortfolio Limited Monoclonal Antibody Therapeutics - Current Market Dynamics & Future Outlook - 1.------ Executive Briefing - 2.------ Introduction - 2.1 --- Definition & Scope - 2.2---- Currently Marketed Monoclonal Antibody Therapeutics - 3.------ Market Size & Growth Rates - 3.1---- Global Market for Monoclonal Antibody Therapeutics - 3.2---- North American Market for Monoclonal Antibody...
Monoclonal Antibodies are Not Always Better - - - - BioNews BioWeb Companies Products BioReports - - - - - Monoclonal Antibodies are Not Always Better For the endpoint of acute transplant rejection, SangStat's (NASDAQ: SANG) Thymoglobulin was more beneficial to kidney transplant recipients than Novartis's (NYSE: NVS) Simulect. Simulect (basiliximab), on the other hand, is an anti-IL-2 receptor monoclonal...
Novartis Press Kit English page 24
author: guestnc1
duplicates:http://www.novartis.com/downloads/press_kit.pdf
Pcr03index-5.0.qxd page 8
author: mcintosht
Therapeutic Biological Approvals FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER - Search - -Therapeutic Biological Approvals - Tradename/ Proper Name Indication for Use STN Manufacturer/ License NoSimulect Basiliximab For the prophylaxis of acute organ rejection in patients receiving...
Pharmaceutical Product List S - Novartis.com Search Novartis.com - Go Novartis.com Home Products Pharmaceutical Best Sellers Pharmaceuticals CIBA Vision Animal Health Over the Counter Infant and Baby Medical Nutrition Diseases and Conditions About Novartis Investor Relations News Center Careers Corporate Citizenship Business Development Countries Contact Help Products -|- Pharmaceuticals - Our Pharmaceutical Products A A- B C A...
http://www.fda.gov/cder/foi/appletter/2003/103764-5040ltr.pdf page 16
http://www.fda.gov/cder/foi/appletter/2003/103764-5040ltr.pdf page 12
http://www.fda.gov/cder/foi/appletter/2003/103764-5040ltr.pdf page 10
http://www.fda.gov/cder/foi/appletter/2003/103764-5040ltr.pdf page 7
http://www.fda.gov/cder/foi/appletter/2003/103764-5040ltr.pdf page 6
http://www.fda.gov/cder/foi/appletter/2003/103764-5040ltr.pdf page 5
http://www.fda.gov/cder/foi/appletter/2003/103764-5040ltr.pdf page 1
BIO Milestones 2001-2002 Biotechnology Information, Advocacy and Business Support | About Us | BIO Events | BIO Members | Join BIO | Member Services | Links | Home CMS Payment System Prescription Coverage & Reimbursement Food & Agriculture Industrial & Environmental Bioethics & Biomedical Research Intellectual Property Regulatory Policies Tax & Fiscal Policies All Issues & Initiatives Press Releases Company...
Approved Biotechnology Drugs, 2002 Biotechnology Information, Advocacy and Business Support | About Us | BIO Events | BIO Members | Join BIO | Member Services | Links | Home CMS Payment System Prescription Coverage & Reimbursement Food & Agriculture Industrial & Environmental Bioethics & Biomedical Research Intellectual Property Regulatory Policies Tax & Fiscal Policies All Issues & Initiatives Press Releases Company...
CBER, Approval letter, Basiliximab, indicated for the prophylaxis of acute organ rejection in patients receiving renal In accordance with approved labeling, your product will bear the trade name Simulect, and will be marketed in single-use glass vials containing 20 mg of Basiliximab Basiliximab to the Center for Biologics Evaluation and Research (CBER) for release by the Director, CBER, under 21 CFR 610.2
Basiliximab - Product Approval Information - Licensing Action FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER - Search - -Basiliximab Product Approval Information - Licensing Action Proper name: Basiliximab Tradename: Simulect Manufacturer: Novartis Pharmaceutical Corp, East Hanover, NJ, License #1244 Indication for Use: Use in renal transplantation in combination with triple...
Basiliximab - Product Approval Information - Licensing Action FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER - Search - -Basiliximab Product Approval Information - Licensing Action Proper name: Basiliximab Tradename: Simulect Manufacturer: Novartis Pharmaceutical Corp, East Hanover, NJ, License #1244 Indication for Use: Include the addition of a new single dose 10mg strength of drug product...
Basiliximab - Product Approval Information - Licensing Action FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER - Search - -Basiliximab Product Approval Information - Licensing Action Proper name: Basiliximab Tradename: Simulect Manufacturer: Novartis Pharmaceutical Corp, East Hanover, NJ, License #1244 Indication for Use: Prophylaxis of acute organ rejection in patients receiving renal...
B.pg 4,6/Das-L/O page 1
author: Rachel Domack
duplicates:http://www.iscpubs.com/articles/abl/b0305das.pdf
Prescription Drug User Fee Act - User Fee Billable Therapeutic Products: Approved Under Section 351 of the PHS Act u/vial MedImmune, Inc License 1252 Synagis Palivizumab 103770/0 6/19/1998 50 mg/vial 100 mg/vial Merck & Co., Inc License 0002 Elspar Asparaginase 101063/0 1/10/1978 10,000 IU/vial Novartis Pharmaceuticals Corp License 1244 Simulect Basiliximab 103764/0 5/12/1998 10 mg/vial 20 mg/vial OMJ Pharmaceuticals, Inc License 1196 Regranex Becaplermin 103691/0 12/16/1997 100 mcg...
Basiliximab, Novartis Pharmaceutical Corp - Package Insert FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER Package Insert Simulect ® (basiliximab) Novartis Pharmaceutical Corp Table of Contents Description Clinical Pharmacology Clinical Studies Indications and Usage Contraindications Warnings Precautions Adverse Reactions Overdosage Dosage and Administration How Supplied References For...
Simulect (basiliximab) Label T2002- 91 89007805 Simulect ® (basiliximab) For Injection Rx only Prescribing Information WARNING Only physicians experienced in immunosuppression therapy and management of organ transplantation patients should prescribe Simulect ® (basiliximab) Simulect ® (basiliximab) is a chimeric (murine/ human) monoclonal antibody...
author: CBER FDA
